• Reported GAAP EPS of $0.82 up 164.57% YoY • Reported revenue of $91.73M • Selling, general and administrative expenses for Soleno Therapeutics are anticipated to increase as the company continues commercialization of VYKAT XR, while also pursuing regulatory approval in other territories, starting with the EU.
Bullish
Soleno Therapeutics achieved strong initial VYKAT XR commercial launch metrics, attained full-year profitability with positive net income, and plans strategic international expansion and pipeline development for DCCR.
Bearish
Soleno Therapeutics faces increasing selling, general, and administrative expenses, significant contingent payment obligations, and inherent product-specific warnings and contraindications for VYKAT XR.